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1. Introduction 
“Cervical cancer is fully preventable and curable, at low cost and at low risk, when 
screening to facilitate the timely detection of early precursor lesions in asymptomatic 
women is available together with appropriate diagnosis, treatment and follow-up” (Lewis, 
M. Pan American Health Organization, 2004). 
The burden of cervical cancer is quite low in the developed countries of the world. The 
situation is quite the reverse in developing countries where it constitutes a major health 
problem. While the incidence is decreasing in the former, it is on the increase in the later. This 
is a source of great concern considering the fact that cervical cancer is preventable and curable 
at low cost with currently available methods. Sub Sahara Africa is the region with the highest 
incidence of cervical cancer in the world with concomitant high mortality affecting women at 
their prime. There are no screening programs for early detection of precancerous lesions 
within the countries of Sub Sahara Africa. Most screening activities are done as pilot or 
research projects which are discontinued on completion. South Africa is the only country in 
the region with a national cytology based screening program since 2001 but then coverage 
remains poor and the impact on invasive cervical cancer is unknown (Louie et al.2009). The 
onset of HIV/AIDS epidemic that is highest in the sub region has elevated the problem of 
cervical cancer to a serious level. To compound the problem is the widespread lack of 
resources associated with the region. The countries of Sub Sahara Africa are shown in figure 1.  
2. Aim 
The aim of this work is to appraise the incidence, mortality, state of prevention and 
treatment of cervical cancer in sub-Sahara Africa. This highlight is necessary so that health 
professionals, philanthropists, policy makers, advocates and other stake holders can 
appreciate and understand the state of the disease and respond through the development of 
treatment, preventive and control programs that will lessen the burden and mortality from 
this disease in the sub region. It is also aimed at highlighting the need to see that cervical 
cancer should be considered a public health problem in the region. 
3. Methods 
The method used was through the synthesis of data and information derived from available 
current published scientific works from peer reviewed journals, workshop proceedings,  
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Fig. 1. Map showing the countries of Sub Sahara Africa (Map Source: www.world map .org) 
(NB Southern Sudan became independent July 2011) 
hospital and regional based cancer registry figures , reports from specific centres, conference 
proceedings and a review of work done on cervical cancer in the authors institution The 
University College Hospital Ibadan Nigeria. 
4. Findings and discussions 
Cervical cancer occurs worldwide but the highest incidence and mortality rates of cervical 
cancer are in Eastern, Western, and Southern Africa, as well as South-Central Asia and South 
America. Rates are lowest in Western Asia, Australia/New Zealand as shown in table 1.  
In sub-Saharan Africa cervical cancer accounts for 22.2% of all cancers in women and it is 
also the most common cause of cancer death among women (Parkin et al.,2003). Cervical  
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World Area Incidence per 100,000 Mortality per 100,000 
Eastern Africa 34.5 25.3 
Western Africa 33.7 24.0 
Southern Africa 26.8 14.8 
South – Central Asia 24.6 14.1 
South America 24.1 10.8 
Melanesia 23.7 16.6 
Middle Africa 23.0 17.0 
Central America 22.2 11.1 
Caribbean 20.8 9.4 
South – Eastern Asia 15.8 8.3 
Central and Eastern Europe 14.5 6.3 
Micronesia/ Polynesia 13.4 4.9 
Eastern Asia 9.6 3.9 
Northern Europe 8.3 2.4 
Southern Europe 8.0 2.6 
Western Europe 6.9 2.0 
Northern Africa 6.6 4.0 
Northern America 5.7 1.7 
Australia/ New Zealand 5.0 1.0 
Western Asia 4.5 2.1 
Table 1. Age Standardized Cervical Cancer Incidence and Mortality Rates by World Area 
(Extracted from GLOBOCAN 2008 by Jemal et al., 2011). 
cancer is however the second common cancer among women after cancer of the breast in 
some areas like Ibadan in Nigeria (Adebamowo et al. 1999). About 60–75% of women in sub-
Saharan Africa who develop cervical cancer live in rural areas. Many of these women go 
untreated, mostly due to lack of access (financial and geographical) to health care. Women 
in sub-Saharan Africa lose more years to cervical cancer than to any other type of cancer. 
Unfortunately, it affects them at a time of life when they are critical to the social and 
economic stability of their families (Parkin et al., 2002).  
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The true incidence of cervical cancer in many African countries is unknown as there is gross 
under-reporting. Only very few countries have functional cancer registries and record-
keeping is minimal or non-existent in many countries. Some of the figures quoted in the 
literature are hospital-based, which represents a small fraction of women dying from 
cervical cancer, as most women cannot access hospital care and die at home. A mortality 
rate of 35 per 100,000 is reported in Eastern Africa. The reported mortality rates in 
developed countries with successful screening programs seldom exceed 5 per 100,000 
women (Chokunonga et al., 2002).  
4.1 Factors responsible for the high prevalence 
4.1.1 Socio-cultural factors 
Human papillioma virus (HPV) has been isolated in most cases of cervical cancer in all parts 
of the world. Epidemiologic studies have shown that the association of genital human 
papilloma virus (HPV) with cervical cancer is strong, independent of other risk factors, and 
consistent in several countries .The International Biological Study on Cervical Cancer 
(IBSCC) Study Group led by Bosch, F. in 1995 reported that HPV DNA was detected in 93% 
of the tumors, with no significant variation in HPV positivity among countries. HPV 16 was 
present in 50% of the specimens, HPV 18 in 14%, HPV 45 in 8%, and HPV 31 in 5%. HPV 16 
was the predominant type in all countries except Indonesia, where HPV 18 was more 
common. There was significant geographic variation in the prevalence of some less common 
virus types. A clustering of HPV 45 was apparent in western Africa, while HPV 39 and HPV 
59 were almost entirely confined to Central and South America. In squamous cell tumors, 
HPV 16 predominated (51% of such specimens), but HPV 18 predominated in 
adenocarcinomas (56% of such tumors) and adenosquamous tumors (39% of such tumors). 
The report concluded that the results confirm the role of genital HPVs, which are 
transmitted sexually, as the central etiologic factor in cervical cancer worldwide (Bosch F et 
al., 1995). Epidemiological studies employing a variety of HPV typing protocols have been 
collated in meta-analyses. HPV-16/18 is estimated to account for 70% of all cervical cancers 
worldwide, although the estimated HPV-16/18 fraction is slightly higher in more developed 
(72–77%) than in less developed (65–72%) regions. About 41–67% of high-grade squamous 
intraepithelial lesion (HSIL), 16–32% of low-grade squamous intraepithelial lesion (LSIL) 
and 6–27% of atypical squamous cells of undetermined significance (ASCUS) are also 
estimated to be HPV-16/18-positive, thus highlighting the increasing relative frequency of 
HPV-16/18 with increasing lesion severity. After HPV-16/18, the six most common HPV 
types are the same in all world regions, namely 31, 33, 35, 45, 52 and 58; these account for an 
additional 20% of cervical cancers worldwide.(Clifford et al., 2006) 
Human papillomavirus (HPV), the necessary cause of cervical cancer, is endemic in 
Africa. In a study to investigate the prevalence of and the risk factors for cervical infection 
with human papillomavirus (HPV) in an inner-city area of Ibadan, Nigeria, Thomas et al., 
(2004) interviewed and obtained a sample of cervical cells from 932 sexually active 
women aged 15 years or older. A total of 32 different HPV types were identified with an 
HPV prevalence of 26.3% overall and 24.8% among women without cervical lesions; or 
age-standardised to the world standard population of 28.3 and 27.3%, respectively. High-
risk HPV types predominated, most notably HPV 16, 31, 35 and 58. In all, 33.5% of 
infections involved more than one HPV type. Unlike most populations studied so far, 
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HPV prevalence was high not only among young women, but also in middle and old age. 
Single women (odds ratio, OR=2.1; 95% confidence interval, CI=1.1–3.9) and illiterate 
women (OR=1.7; 95% CI=1.1–2.5) showed increased HPV positivity.. High prevalence of 
HPV in all age groups may be a distinctive feature of populations where HPV 
transmission continues into middle age and cervical cancer incidence is very high. Many 
of the factors that increase both HPV acquisition and promote the oncogenic effect of the 
virus are also very widespread in Africa (Schmauz et al 1989). These include: early 
marriage, polygamous marriages and high parity. Polygamy is reported to increase the 
risk of cervical cancer two-fold and the risk increases with increasing number of wives 
(Bayo et al., 2002). This is part of the male factor in addition to prostitution that lead to the 
high prevalence of HPV in Sub Sahara Africa.  
High parity, which is the norm in some cultures in Africa, is also a recognised, HPV-related 
co-factor for the development of cervical cancer (Brinton et al 1989).  
The prevalence of HPV has been shown to be higher in uncircumcised men than in 
circumcised men. In a study to investigate the association between male circumcision 
(MC) and high risk human papilloma virus (HR-HPV) prevalence, Auvert and colleagues 
(2009) using urethral swabs collected during a period of 262 consecutive days among 
participants from the intervention (circumcised) and control (uncircumcised) groups who 
were reporting for a scheduled follow-up visit reported that HR-HPV prevalences among 
intervention and control groups were 14.8% (94/637) and 22.3% (140/627). Confounder 
factors (ethnic group, age, education, sexual behaviour including condom use, marital 
status, and HIV status) had no effect on the results. Multiple HR-HPV prevalence was 
7.0% (89/1267) It was significantly lower among men of the intervention group compared 
with men of the control group (4.2% vs. 9.9%) .The prevalence of HR-HPV infections in 
their study was even thought to be underestimated since detection in the urethra is 
significantly lower than detection in the glans, corona sulcus or the penis shaft. As a 
corollary, some randomized controlled trials have shown a partial protective effect of 
male circumcision (MC) on the acquisition of HIV by males in Africa. The effect of MC on 
HR-HPV reinforces the WHO-UNAIDS recommendation for the implementation of MC 
programs in countries with a high HIV prevalence, a low MC prevalence and a high MC 
acceptability (Auvert et al., 2009). In Sub Sahara Africa these countries are mainly in 
Southern and Eastern Africa. Drain et al., in 2006, published an analysis of classification of 
developing countries according to prevalence of male circumcision. The categories were 
low, 20%, intermediate 20-80% and high > 80%. The classification for developing countries 
in Africa is presented in table 2. 
This report noted that male circumcision, which is routinely practiced in the Middle East, 
Northern and Western Africa, and Western Asia, was associated with lower rates of certain 
STIs, HIV and cervical cancer (a proxy for HPV), but not with infections transmitted by non-
sexual routes. In general, more male circumcision was strongly associated with lower 
cervical cancer rates and fewer HIV cases, independent of religion. Furthermore, male 
circumcision was independently associated with HIV among countries with primarily 
heterosexual HIV transmission, and not among countries with primarily homosexual or 
injection drug use HIV transmission. These findings all suggest that male circumcision is a 
true protective factor that reduces the sexual transmission of HIV and possibly HPV, 
independent of Muslim and Christian religions. 
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Male circumcision prevalence 





Burundi Cote d’ivoire Angola Kenya 
Cape Verde Ethiopia Benin Liberia 
Malawi Lesotho Burkina Faso Libya 
Namibia Mozambique Cameroon Madagascar 
Rwanda South Africa Chad Mali 
Swaziland Sudan Congo (Brazzaville) Mauritania 
Zambia Tanzania Dem Rep of Congo Mauritius 
Zimbabwe Uganda Djibouti Morocco 
  Egypt Niger 
  Equatorial Guinea Nigeria 
  Eritrea Senegal 
  Gabon Sierra Leone 
  Gambia Somalia 
  Ghana Togo 
  Guinea Tunisia 
Table 2. Category of male circumcision prevalence for developing countries in Africa 
(Adapted from Drain et al., 2006)  
4.1.2 Socio-economic factors 
Worldwide women of low socio-economic status have a greater risk of having cervical 
cancer. Cervical cancer is often referred to as a disease of poverty and of poor women. A 
recent study in Mali in West Africa showed that within a population widely infected with 
HPV, poor social conditions, high parity and poor hygienic conditions were the main co-
factors for cervical cancer (Palacio-Mejia et al., 2003). Sub Sahara Africa also has widespread 
conditions that encourage sub standard living conditions. These include wars, political 
chaos, internal conflicts, natural disasters, famine and drought. These often lead to large 
populations being displaced externally and internally for long periods of time. Under this 
refugee- like conditions, social vices like rapes, prostitution and multiple marriages and 
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cohabitation prevail encouraging the transmission of HPV. War is associated with male 
sexual promiscuity, which in turn contributes to the development of cervical cancer among 
sexually monogamous women. In 1996, a case–control study sponsored by Stanford 
University documented that the Vietnam War had contributed substantially to the problem 
of cervical cancer in contemporary Vietnam, and the Vietnam/American Cervical Cancer 
Prevention Project was established as an all-volunteer non profit organization. Publication of 
data linking war to disease was delayed for 8 years in an attempt to ease the process of 
reconciliation by offering what most would acknowledge to be a remedy in advance of what 
some will perceive to be an accusation. (Suba et al., 2006)  
High rates of invasive cervical cancer was noted in coastal areas of Coasta Rica and this was 
attributed to difficulties in having access to treatment. Most countries of Sub Sahara Africa 
are located within the Tropical Rain Forest with difficult terrain as there are lots of swampy 
areas and thick and mountainous forests. This makes access to screening, health education 
and treatment difficult. 
4.1.3 Biological factors 
Poor nutritional status and infections, e.g. malaria, HIV and TB, are ravaging sub-Saharan 
Africa and have made many people immuno-compromised. Several studies have 
demonstrated the association of HIV with HPV. The prevalence of CIN has been estimated 
to be as high as 20–40% in HIV-positive women (Wright et al 1994). HIV-positive women are 
more likely to have persistent HPV infections than HIV-negative women. In a study of 2,198 
women who attended gynaecological clinics in Abidjan, Côte d'Ivoire, HIV-positive women 
had a significantly higher prevalence of squamous intraepithelial lesion (SIL) (La Ruche et 
al., 1998). Temmerman et al (1999) reported a five-fold increased risk of high-grade SIL 
among 513 HIV-positive women in a family planning clinic in Kenya. Other reports from the 
region show that women with HIV develop cervical cancer at an earlier age than women 
who are HIV-negative(Moodley 2001). Gichangi et al(2003) in Kenya found that young 
women under the age of 35 who had invasive cervical cancer were 2.6 times more likely to 
be HIV positive than controls of similar age (35% vs. 17%, OR 2.6, p=0.043). A recently 
published study from Tanzania showed that the prevalence of HIV-1 was much higher 
among the cervical cancer patients (21.0%) than among the controls (11.6%). HIV-1 was a 
significant risk factor for cancer of the cervix (OR=2.9, 95% CI=1.4–5.9).(Moodley et al., 2006) 
Sub-Saharan Africa harbours 67% of the world's population of people living with HIV and 
AIDS (Buga G 1998).  
4.1.4 Lack of awareness and knowledge of cervical cancer in Africa 
Cervical cancer is yet to be recognised as an important public health problem in sub-Saharan 
Africa. In Sub Sahara Africa, priority is given to infectious diseases such as malaria, 
tuberculosis, leprosy, diarrheal diseases, acute respiratory infections and HIV/AIDS all of 
which have preventive and management strategies. Several studies have shown poor 
knowledge of cervical cancer in Africa, which cuts across different literacy levels. Among 
500 attendees of a maternal and child health clinic in Lagos-Nigeria only 4.3% were found to 
be aware of cervical cancer. (Anorlu et al., 2004) In 2004, also in Lagos-Nigeria, 81.7% of 139 
patients with advanced cervical cancer had never heard of cervical cancer before, and 20%, 
30% and 10% respectively thought the symptoms they had were due to resumption of 
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menses, lower genital infection and irregular menses. Almost all the women (98%) believed 
that their advanced disease was curable, 12% thought it was not a serious disease and only 
9% understood that it was cancer and therefore serious (Ajayi et al., 1998). Similar studies in 
Kenya and Tanzania also reported very poor knowledge of the disease in patients. (Gichangi 
et al., 2003 & Kidanto et al., 2002). Poor knowledge is not limited to patients alone, however; 
health care workers who are supposed to be better informed do not have good knowledge 
of the disease either. In Lagos Nigeria, delay by primary health care providers in referring 
cases of cervical cancer was found to be an important cause of women presenting with late-
stage disease. It took a mean of 9.35 ± 12.9 months for primary health care providers to 
diagnose and refer women with cervical cancer to a tertiary hospital for management. 
(Anorlu et al., 2004).  
Education improves knowledge and acceptability of preventive measures against cervical 
cancer. In a study on cervical cancer awareness and HPV vaccine acceptance among 375 
female university students in Northern Nigeria, a total of 133 participants knew of HPV 
(35.5%), 202 (53.9%) had heard of cervical carcinoma and 277 (74.0%) were willing to accept 
HPV vaccination. (Ilyasu et al., 2010). Apochie and colleague (2009) conducted a cross 
sectional survey among college students aged 18 years and above, attending a large 
university in Accra, Ghana. A sample of 157 students was selected to study knowledge and 
beliefs about cervical cancer screening. In general, respondents seemed to understand that 
cervical cancer screening had benefits. Over 64 percent believed that the test could find 
cervical changes before they became cancerous while 78.5% thought those changes could be 
easily cured. Among the perceived barriers to screening, the most prevalent perceived 
barrier was that only half of respondents believed that the purpose of cervical cancer was to 
diagnose cancer, the second commonest reported barrier (40.6%) was the belief that their 
partner would not allow them to obtain cervical cancer screening. The following barriers 
were also important; cost (23.2%), not knowing where to go (24.3%), and belief that 
everyone would think they were sexually active (24.6%). Encouragingly, few believed that a 
pap test would be painful (9.4%). While more than 68% perceived that young women were 
susceptible to cervical cancer, a lower percentage (52.5%) believed that they themselves 
were at risk for cervical cancer. About three quarters of respondents (73%) believed that 
cervical cancer was a serious disease that would make a woman's life difficult and about 
62% of students also believed that there were effective cures for cervical cancer. In general, a 
low percentage received screening cues from their social environment by way of knowing 
peers who had screened or from a healthcare worker‘s recommendation. Six of the fifteen 
respondents who had received at least one recommendation from a healthcare worker to get 
cervical screening, scheduled and obtained one. The subset reporting having received a 
health care worker recommendation but that reported not having the test, indicated the 
following reasons; they could not afford it, they did not know where to get screening, they 
had no time to schedule and obtain screening and they felt it was embarrassing to expose 
themselves for screening. About a third reported ever having heard a mass media 
discussion on cervical cancer while a fifth have at least once listened to a discussion on 
cervical cancer at a church or other social gathering. About half also stated that they would 
be willing to obtain the cheaper alternative cervical cancer screening using visual inspection 
and mild acetic acid, if a doctor recommended it. Overall there was good awareness of the 
issues related to screening, although there were specific gaps in knowledge about risk 
factors and screening intervals. For instance, it was found that although the relationship 
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between sex and cervical cancer was known, less was known about other risk factors like 
their partner's prior sexual experiences and very little was known about the link between 
HPV and cervical cancer. 
4.1.5 Poor cervical cancer screening 
Very few women in sub-Saharan Africa are ever screened for cervical cancer. None of the 
500 women attending a maternal and child health clinic in a poor area of Lagos in 1999 
had ever had a Pap smear .Only 9% of health care workers in two health institutions in 
Nigeria had ever had a Pap smear. In a study among medical workers in a Ugandan 
hospital (doctors , nurses and medical students) Only 19% of the female medical workers 
had ever had a cervical cancer screening test done. The reasons for not having been 
screened included: not feeling at risk, lack of symptoms, carelessness, fear of vaginal 
examination, lack of interest, test being unpleasant and not yet being of risky age. 
Moreover, 25% of the female respondents said that they would only accept a vaginal 
examination by a female health worker.(Mutyaba et al., 2006) In a similar study among 
nurses in a Tanzanian hospital concerning nurses' own cervical cancer screening practices 
most (116/137) of the respondents had never had a Pap smear the most common reason 
(54.7%) was not knowing where to go for the test, followed by seeing no reason for the 
test (13.1%), being afraid of the procedure (9.5%) and being afraid of bad results 
(7.3%).(Urasa & Darj 2009) 
Some of the few women who do have access to screening do not get themselves screened 
because they have wrong beliefs about cervical cancer. (Anorlu et al., 2007). Less than 1% of 
women in four West African countries had ever been screened (Gichangi et al., 2003). 
Moreover, there are very few cervical screening services in Africa and many of them are 
based in secondary and tertiary health care facilities located in urban areas. Only 5% of 504 
general practitioners in Lagos Nigeria in 2004 screened their patients (Denny et al 2006). 
Women who use these services are generally young, and smears are thus being taken from a 
relatively low-risk group. 
Screening in most developing countries like the countries within the sub region is mainly 
opportunistic, characterized by an estimated low coverage, coexisting with over-screening 
of women with access to health services, and an absence of quality control procedures. 
Policies for cervical cancer screening in most countries vary and, most often nonexistent . 
Formulation and ensuring compliance with national program guidelines is an essential step 
toward significantly reducing the burden of cervical cancer (Arrosi et al. 2010). This type of 
service does not reach women most at risk, i.e. older women aged 35–60 years, especially 
those who live in rural areas. Cytology-based screening, which is used in developed 
countries, is resource intensive, and difficult to realise in very many countries in sub-
Saharan Africa because of poor health care infrastructure and lack of resources. There are 
very few cytopathologists, cytoscreeners and cytotechnicians; some have inadequate 
training. Quality control is inadequate. Histopathological services are extremely limited in 
many countries. Malawi, a country with a cervical cancer incidence rate of 47 per 100,000 
women, had one pathologist, one colposcope, no cyto-technicians and no facilities for 
cervical cancer screening or treatment as at 2001. The situation is not much different 
presently. The default rate among those with cytological abnormalities reaches 60–80% due 
to the absence of effective mechanisms for recall of women with abnormal smears. 
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The effectiveness of direct visual inspection [visual inspection with acetic acid (VIA) and 
visual inspection with Lugol's iodine (VILI)) as a form of population-based screening has 
been studied across the continent, mainly sponsored by international agencies (Chirenje et 
al., 2001) VIA is similar to colposcopy in that 4% acetic acid is applied to the cervix and any 
acetowhite lesion is visualized, although with VIA there is no magnification. It is a simple 
procedure and in most centres has been carried out by trained nurses. Candidates with 
suspicious lesions are selected for treatment. Studies have shown the sensitivity of VIA to be 
the same as that of Pap smear while its specificity is lower than 85% (Urasa & Darj 2011). 
The specificity is also noted to be even lower among HIV positive patients possibly due to 
high rates of coinfections in the lower genital tract (Denny et al., 2002). Visual inspection 
method is however a subjective method and prone to different interpretations by different 
observers depending on experience and competence. Other screening methods include HPV 
DNA assay (which has been shown to be even superior to PAP smear test) and colposcopy. 
4.1.6 Treatment of cervical cancer in sub-Saharan Africa 
Treatment of cervical cancer is dependent on the stage of the disease, age and medical state 
of the patient, tumor characteristics, patients' preferences and resources within the health 
sector of each country. Options can be monotherapy or combined; they range from 
conisation of the cervix, simple hysterectomy with or without lymphadenectomy, radical 
hysterectomy with pelvic lymphadenectomy, pelvic exenteration, chemotherapy, 
radiotherapy, to palliative chemotherapy. Treatment at an early stage has the best prognosis 
with the highest cure rates (Urasa & Darj 2011) 
4.1.6.1 Treatment of pre-invasive cervical cancer 
It may not be too wrong to say that there are apparently more cases of invasive cancer than 
pre-invasive cancer; this is mainly because there are very few facilities for screening and 
very poor access to the screening services. Because so few women are ever screened, not 
many cases of pre-cancerous lesions are diagnosed or detected. Colposcopy is available only 
in very few centres. Hysterectomy and cone biopsy are the usual treatment modalities for 
pre-cancerous lesions, as the equipment and expertise for large loop excision of the 
transformation zone (LLETZ), also known as loop electrosurgical excision (LEEP), are 
scarce.  
4.1.6.2 Treatment of invasive cervical cancer 
The treatment of invasive cervical cancer continues to be a major challenge in many sub-
Saharan African countries, due to the lack of surgical facilities, skilled providers and 
radiotherapy services. Management of women with invasive cervical cancer requires a 
multidisciplinary approach, including: gynaecologists, radiation oncologists, medical 
oncologists, pathologists, medical physicists, technicians, nurses and counsellors. These 
specialists are lacking in many places across the continent, and where they exist they tend to 
work in isolation rather than in teams. 
There are few cases that present in the operable stage of the disease. In Lagos Nigeria, less 
than 10% of cases are operable at the time of presentation. Some of the few who do present 
early may not have surgery as there are very few certified gynaecologists who perform 
radical gynaecological cancer surgery. Follow-up after surgery is often very poor as some 
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patients who believe they have been cured never come back. Others just cannot afford the 
cost of transportation back to urban centres for follow-up (Ashraf, H. 2003). For patients 
who present late, radiotherapy becomes the preferred treatment. Unfortunately, only a few 
receive this treatment due to the paucity of resources and very advanced disease at 
presentation. Chirenje et al. (2001) found in Harare, Zimbabwe that in 70% of patients, 
radiotherapy was the most commonly used treatment modality, as many of the cases 
presented with stage 2B and above.  
Radiotherapy is not available in many places in Sub Sahara Africa. In 1997, radiotherapy 
was not available in 32 African countries. (Levin et al.,1997). In 2003, 15 countries in Africa 
did not have a single radiotherapy machine. Nigeria, the most populous country in Africa, 
had only five radiotherapy centres as at 2009: four government-owned and one privately 
owned. WHO recommends 0.4 radiotherapy machines per million of population. Nigeria's 
five machines to 140 million people translates to ∼0.04 per million, well below WHO’s 
recommendation. In contrast, in the United States, there are 12 machines per million people. 
(Sepulveda et al., 2003). Besides few machines, those that exist frequently do not function 
most of the time because the resources for their proper maintenance and repair do not exist. 
In addition, there is a shortage of trained staff such as radiotherapists and medical 
physicists, as well as essential materials.  
4.1.7 Supportive care 
Pain is the most common presenting symptom in many cancer patients in Africa because of 
late presentation. In a survey of terminally ill patients in five countries in Africa – Uganda, 
Ethiopia, Tanzania, Zimbabwe and Botswana – the greatest need expressed by the patients 
was pain relief. (Harding et al., 2005) In another study comparing the concerns of terminally 
ill patients in a developed country (Scotland) and an African country (Kenya), it was found 
that the main concern of the Scottish patients was the emotional pain of facing death, while 
for their counterparts in Kenya it was physical pain and financial worries. Unfortunately, 
there is inadequate availability of pain-relieving medications, especially opioids. Only 11 
out of 47 African countries use morphine for chronic pain and of these 11, the amount 
consumed is small. (Murray et al 2003) . 
Oral morphine is not available to very many cancer patients in sub-Saharan Africa. 
Insufficient funds due to low priority accorded to palliative care by governments, regulatory 
and pricing obstacles, ignorance, and false beliefs are responsible. In some instances, where 
drugs are available to patients, sustainability of pain relief is hampered by poverty, as many 
cannot afford the cost of the drugs. Poverty, poor infrastructure, lack of health care workers 
adequately trained in palliative care and poor priority accorded to palliative care by African 
governments are all obstacles to effective palliative care in sub-Saharan Africa. There are 
very few hospices to take care of terminally ill patients. However, countries like South 
Africa, Uganda, Kenya, Tanzania, Nigeria and Zimbabwe have made some progress in 
palliative care. Uganda is the first African country to follow the WHO guidelines on 
palliative care. It has made oral morphine freely available to districts that have specialist 
palliative care nurses or clinical officers, and has promoted morphine use down to the 
villages. Laws have also been passed to allow trained nurses, especially those in the rural 
areas, where there are very few or no doctors, to prescribe morphine. Cancer is believed in 
certain cultures to be a punishment from the gods, and terminally ill patients often seek help 
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from traditional healers and spiritual leaders. A good model for palliative care in Africa 
should therefore integrate the culture, beliefs and traditions of the people. Some countries 
are making efforts in this direction by incorporating traditional healers into mainstream 
medicine. However, a feasible, accessible, and effective palliative care is yet to be developed 
in sub-Saharan Africa. (Merriman & Kaur 2005).  
4.2 Improvements in outlook 
There is need to improve the outlook of this condition in Sub Sahara Africa. There should be 
improvement in attitude towards education needs of the populace so as to create and 
improve awareness and knowledge about the disease. Disease prevention requires social 
change, which in turn requires the participation of those for whom the change is intended, 
including demographic groups at high risk for disease, appropriate governmental 
authorities, and essential medical personnel. Both locally and globally, socio-political 
problems associated with sustaining working coalitions from groups with shared interests 
but competing incentives constitute critically important real-world obstacles to successful 
cervical cancer prevention and will remain so irrespective of the screening method(s) 
eventually used. In settings where health systems cannot afford to ignore such incentives, 
laboratory data constitute an essential yet sometimes overlooked fulcrum against which to 
leverage the social change required to preserve life (Suba et al., 2006)  
There is need for sensitisation of health workers about cervical cancer and importance of 
screening. Based on studies carried out in countries where organized screening is available, 
it is known that screening uptake can be influenced by cultural beliefs, the social position of 
women, characteristics of the health care system, the physician's attitudes towards screening 
and women's comprehension of the screening process. Embarrassments about undergoing a 
gynecological examination, fear of the procedure or belief that little can be done to prevent 
cancer are other factors that might decrease screening participation. Lower socio-economic 
background, lack of health insurance and low literacy also compromise participation in 
screening. Attending cervical cancer screening may have a negative connotation or stigma 
when it is combined with a gynecological examination and treatment for reproductive tract 
infections. The gender of health care professionals and limited time that they allocate to 
patient education may negatively influence screening participation as well. Other influences 
that may influence participation in screening in particular in low resource countries are 
gender imbalances and whether illness is perceived as traditional or modern. Adequate 
knowledge about cervical cancer influences early detection and treatment seeking pattern 
(Mutyaba et al., 2007). In Botswana a national cervical cytology screening committee was 
formed in 1996 with a role in planning and advising the government. Just six years later a 
national guidance document for the national cervical cytology programme was drawn up 
and implemented. In this short space of time public awareness has been successfully raised 
resulting in an increased uptake of Pap smears from 5000 per year before the start of the 
programme to an impressive 32,000 per year in 2009. Despite considerable success, progress 
is hampered by inadequate resources, the high prevalence of HIV in the country and the 
long waiting list for treatment. 
There is now a need to build upon the scope of cervical cancer prevention. This problem is 
not limited to Botswana as many African countries have similarly inadequate resources to 
treat patients even when abnormal cervical cytology is detected (sSACCWG 2010). Training 
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curricula of nurses and medical students need to be revised to include more practical 
cervical cancer screening skills. There is need to change attitudes that screening is only for 
gynaecologists. For opportunistic screening to work, health workers in other departments 
need to be sensitised on the gravity of cervical cancer and to remember to refer all eligible 
women who come into their care for screening (Mutyaba 2006). Nurses in high income 
countries play a role in cancer prevention and participate in cervical cancer screening by 
carrying out Pap smear tests . Due to the lack of logistics and scarcity of gynecologists and 
pathologists in Sub Sahara Africa ,nurses could be used effectively in the prevention of 
cervical cancer, by being enabled to collect Pap smear tests specimen and using the visual 
inspection by acetic acid technique which is less costly and does not require high expertise 
(Urasa & Darj 2011). 
Facilitation of screening activities through the provision of more PAP smear facilities while 
the evaluation and adoption of non cytological based screening methods such as use of VIA 
and Lugols iodine and HPV DNA testing and ensuring wider coverage of screening 
activities is desirable. In developed area with low mortality rates from cervical cancer , it has 
long been established that organized screening programs has great impact on the reduction 
of cervical cancer mortality. Time trends in mortality from cervical cancer in Denmark, 
Finland, Iceland, Norway, and Sweden since the early 1950s were investigated in relation to 
the extent and intensity of organised screening programmes in these countries. In all five 
countries the cumulative mortality rates (0-74 years) fell between 1965 and 1982. In Iceland, 
where the nationwide programme has the widest target age range, the fall in mortality was 
greatest (80%). Finland and Sweden have nationwide programmes also; the mortality fell by 
50% and 34%, respectively. In Denmark, where about 40% of the population are covered by 
organised programmes, the overall mortality fell by 25%, but in Norway, with only 5% of 
the population covered by organised screening, the mortality fell by only 10%. The results 
support the conclusion that organised screening programmes have had a major impact on 
the reduction in mortality from cervical cancer in the Nordic countries.(Laara E et al., 1987) 
It has been established that cytologic screening programs that detect and treat precancerous 
lesions decrease mortality from cervical cancer in countries that have been able to achieve 
broad screening coverage at frequent intervals. However, in the majority of low-income 
countries like Sub Sahara Africa, cytologic screening has proven difficult to sustain, in large 
part because of its reliance on highly trained cytotechnologists, high-quality laboratories, 
and an infrastructure to support up to 3 visits for screening, colposcopic evaluation of 
abnormalities, and treatment. 
Several factors have led to an expansion of the options for cervical cancer control. First, the 
availability of reliable HPV DNA assays has led to numerous studies documenting its higher 
sensitivity for detecting precancerous lesions compared with a single cytology test. Second, 
recent studies suggest that alternate screening strategies that use HPV DNA testing or simple 
visual screening methods may be more practical in some areas of the world like Sub Sahara 
Africa. Third, regardless of initial screening test (e.g., cervical cytology, HPV DNA testing, 
simple visual screening), strategies that enhance the linkage between screening and 
treatment, and seek to minimize loss to follow-up, have the best chance of measurable 
success. Additionally, economic evaluations of these alternatives have concluded that they 
are promising (Goldhaber-Fierbat & Goldie 2006). It has been suggested that the most 
efficient and cost-effective screening techniques in low-resource countries include visual 
www.intechopen.com
 
Topics on Cervical Cancer with an Advocacy for Prevention 64
inspection using either acetic acid or Lugol’s iodine and DNA testing for human 
papillomavirus (HPV) DNA in cervical cell samples (Sankaranarayanan et al., 2009 cited in 
Jemal A. et al., 2011) A recent clinical trial in rural India, a low-resource area, found that a 
single round of HPV DNA testing was associated with about a 50% reduction in the risk of 
developing advanced cervical cancer and associated deaths. The limitations of HPV DNA 
testing include the cost (i.e. US$20–30 per test), infrastructure, and time needed to obtain a 
result . However CareHPV (Qiagen Gaithersburg Inc., MD, USA) has been developed as a 
simple, rapid and operational HPV test for low-resource settings that can produce results 
within 3 h. The compact, portable and battery-operated technology has stable conditions, and 
the test can be conducted by workers with minimal training. Data from China showed that, 
compared to VIA, CareHPV has a higher sensitivity (90% vs. 41%) and a reasonably 
comparable specificity (84% vs. 94%) to detect high-grade lesions. Moreover, a modelling 
analysis found that CareHPV has the potential to reduce the incidence of cervical cancer by 
56% in China if given just three times over a woman’s lifetime and effective treatment is 
available, suggesting its potential impact in reducing the burden of invasive cervical cancer in 
comparable settings. Regulatory approval is anticipated in developing countries in the near 
future, and CareHPV test if provided at a low cost, represents a promising alternative 
screening test, however, its performance and diagnostic value to detect pre-cancerous lesions 
need to be evaluated in African settings (Louie et al., 2009). 
Widespread adoption of HPV vaccination to the recommended target population will 
reduce the disease incidence in the future. The vaccine is however seen to demobilize efforts 
towards setting up and improving screening services in places with poor screening 
coverage. The high cost of the vaccines is a constraint on low resource countries that have 
high incidence of the disease. It has been submitted that the vaccines if given to girls before 
onset of sexual activity, have the potential to dramatically reduce the incidence of HPV 
infection and therefore cervical cancer. Mclntyre, P. ( 2011) however also reported that one 
problem is that it is unlikely that the benefits will start to be felt in 15-20 years, and the full 
population impact will take 50 years or more to be felt. He is of the view that implementing 
an HPV Vaccination program is no substitute for organizing an effective screening system. 
The vaccine is of little value to the population of women who have already become sexually 
active as it cannot eradicate the virus if already present or retard the growth of incipient 
cancer. The report also noted that despite impressive results in clinical trials, they have not 
yet proven themselves in country programs. An example was the program in Romania 
where free vaccine was provided to girls 11 years old and a school – based campaign 
program of vaccination was started. It was reported that the take up rate was as low as 4%. 
Some parents prevented their daughters from getting vaccinated raising public health aspect 
issues towards high coverage and acceptance. The vaccine is therefore seen by some as a 
possible distraction from the main challenge as “the vaccine is not an alternative to cytology. 
We cannot fight cancer without regular cytology examination and that must be clearly 
stated” ( Chil, A., quoted in Mclntyre 2011) . The expectations that vaccines which primarily 
protect against the most common strains of HPV infections (HPV types 16 and 18), which 
cause about 70% of cervical cancers, may prevent cervical cancer worldwide are at present 
high. The vaccines have shown high safety, efficacy and immunogenicity for both the 
quadrivalent HPV 16 ⁄ 18 ⁄ 6 ⁄ 11 vaccine (Gardasil_, Merck & Co., Inc.) and the bivalent HPV 
16 ⁄ 18 vaccine (Cervarix_, GlaxoSmithKline Biologicals) (Schiller et al. 2008 cited in Louie Et 
al., 2009). A number of countries in sub-SaharanAfrica have licensed the HPV vaccines 
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(Table 3). However, implementation plans are lagging and will depend largely on the 
affordability of the vaccines, and a clear cost benefit ratio. However, affordable pricing is the 
most critical factor to facilitate the introduction of HPV vaccines in low- and medium-
resource countries like Sub Sahara Africa in the short term. It is also extremely important 
that women continue to receive screening services because the current vaccines are being 
given to adolescent girls only, and even vaccinated girls should begin screening when they  
 
Quadrivalent HPV 6/11/16/18 Vaccine  
(Gardasil ® Merck, SA) 
Bivalent HPV 16/18 Vaccine  
(Cervarix ®, GSK) 
Botswana Congo 
Burkina Faso Cote d’Voire 
Cameroon Gabon 




Cote d’Ivoire Nigeria 
Democratic Republic of Congo Senegal 







South Africa  
Togo  
Uganda  
Table 3. HPV Vaccines licensure in Sub Sahara Africa as of March 2009 ( Source: HPV 
Information centre, 2009 cited in Louie et al., 2009) 
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HPV Prevalence




6 0.4 0.2 0.0 1.4 
11 0.5 0.3 0.0 1.1 
16 51.6 53.4 36.5 49.4 
18 18.1 15.1 29.4 24.8 
31 2.5 2.8 0.0 2.3 
33 6.2 6.4 5.3 5.9 
35 4.1 2.5 1.5 8.4 
39 1.1 1.5 0.0 0.3 
45 9.1 8.3 8.2 11.3 
51 3.1 1.4 1.5 8.5 
52 3.4 1.9 0.0 8.7 
56 0.7 0.8 0.0 0.5 
58 1.3 1.1 0.0 2.4 
59 0.7 0.6 1.5 0.7 
66 0.6 0.6 0.0 0.8 
68 1.1 1.1 0.0 1.4 
70 0.1 0.0 0.0 0.0 
73 0.7 0.8 0.0 0.0 
82 0.0 0.0 0.0 0.0 
Table 4. Type – specific HPV prevalence among invasive cervical cancer cases in Africa by 
histology.( Source: WHO/IDC HPV information centre). 
reach the recommended screening age since the vaccines do not provide protection for the 
30% of chronic infections by HPV types other than HPV 16, 18, 6 and 11 that cause cervical 
cancer as shown in table 4 and that even in the recommended strains, protection is not 100% 
(Sankaranarayanan , 2009a, 2009b).  
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Prevention and early diagnosis through vaccination and screening requires effective 
mobilization of the target groups and this has been a problem in developing countries like 
the countries of Sub Sahara Africa. An approach to improve this has been formulated by 
Alliance for Cervical Cancer Prevention (ACCP) as follows. Since cultural and emotional 
barriers and practical needs are among the main reasons why women choose not to be 
screened, addressing these barriers and needs will help increase women’s awareness and 
willingness to seek services. Screening, treatment, and follow-up services need to address 
women’s cultural, emotional, and practical needs and concerns. 
Community involvement is essential for: Using a community-based education approach as a 
way of building a discourse with women and promoting women’s participation will help 
reduce fear and misunderstanding about cervical cancer screening and treatment and 
strengthen prevention knowledge and practices. Making women’s experiences with services 
more positive ensures greater follow-up rates and increases the likelihood that women will 
share information about their good experience with peers. Reducing their fear of screening 
and treatment Strengthening women’s understanding of prevention. Efforts in creating 
effective messages to improve women’s awareness is needed. Messages should be targeted 
to reach women at highest risk of cervical cancer (generally aged 30 -50 years). Women 
should be involved in creating prevention messages and programs. Recognized barriers to 
women’s participation in screening include: little understanding of cervical cancer, limited 
understanding of female reproductive organs and associated diseases , lack of access to 
services, shame and fear of a vaginal exam, fear of death from cancer, lack of trust in health 
care system, lack of community and family support. Common misconceptions about cervical 
cancer include the fact that people often do not know that it is preventable and the belief 
that screening involves Sexually Transmitted Infections (STI)/HIV screening including the 
belief that a positive/abnormal Pap smear result means a woman will die. In South Africa 
and Kenya, women often think a positive screening test means they have HIV infection 
While in Mexico, women fear that treatment will leave them sexually disabled. 
Direct personal contact can facilitate screening exercises. This can be done through 
community meetings, posters, pamphlet newspaper advertisements or articles and radio or 
television messages. Key sources of information include peers who have received messages 
or been screened, leaders or members of women’s groups, midwives and traditional healers 
,community health promoters, community leaders ,nurses, nurse practitioners, or doctors. 
The target groups have to be located. Places to reach women are local women’s groups 
community centres, women’s workplaces, places of worship ,health facilities, women’s 
homes, schools (parent’s groups) and markets and key cervical cancer prevention messages 
should include the facts that good health practices can help prevent cancer, cervical cancer 
develops slowly and is preventable, screening can detect treatable, precancerous lesions 
before they progress to cancer, women aged 30 and older are more likely to develop cervical 
cancer than younger women, women in their 30s and 40s should be screened and that the 
screening procedure is relatively simple, quick, and is not painful. A small number of 
women who need treatment after screening can receive a simple procedure to remove the 
lesion. Screening test that is positive is not a death sentence but it provides the opportunity 
to eliminate abnormal cells before they become cancerous 
Helping women discuss cervical cancer can bring the message home. This can be done 
through community health or outreach workers who can facilitate communication at the 
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community level. Counselling by health care providers can both inform women and help 
them talk to their families. Women who receive treatment for precancerous lesions and 
who must abstain from sexual intercourse for several weeks especially need good 
counselling 
To ensure women’s positive experiences with screening, there is need to build and maintain 
positive provider-client relationships. This is needed because women are more likely to 
participate when they are treated well, health care providers are sensitive, responsive and 
respectful. Health care providers should develop a respectful rapport with clients. Women 
with positive experiences will become advocates when talking to other women. 
Important counselling tips include listening and encouraging women to express their 
concerns being sensitive to cultural and religious considerations expressing support through 
non-verbal communication, such as nodding, keeping messages simple and answering 
questions directly, calmly, and in a reassuring manner and providing adequate information 
to remind them of the instructions. Services should be made accessible and appropriate 
through review of internal policies and procedures to ensure that programs are accessible 
and friendly to women. Having female health care providers in settings where women are 
uncomfortable with male health care providers, if possible can help. Ensuring affordability 
of the services and having settings that will ensure confidentiality and privacy including 
easy access to the women are essential. Local languages should be incorporated into the 
counselling medium. This can be done through involving women helps who can also assist 
in developing, implementing and evaluating programs and messages. Advisory team of 
women and other key community leaders can be consulted in order to deliver a package 
that will meet women’s cultural, emotional and practical needs. This is aimed at increasing 
women’s awareness of and willingness to seek services and improve women’s experience 
with cervical cancer prevention services in addition to increasing program participation 
among women at risk. 
High parity is associated with increased incidence of HPV infection leading to increased 
cases of cervical cancer. Most women in the region have high number of children resulting 
in worsening poverty and predisposition to the disease. Education on the need for reduced 
family size through the adoption of effective family planning methods can help in 
improving the general living condition of the people. This will eventually lead to sizeable 
population that can be easily reached with cervical cancer control programs. 
Onset of sexual activities among teenage girls in the sub region from the age of 15years is 
high . This predisposes such girls to high risk of cervical cancer. The promotion of use of 
condom early through sex education programs in early school days can also help in 
reducing the transmission of HPV in the sub region. Closely linked to this is the issue of 
circumcision which should be encouraged among those with low level of practice.  
Adoption of radiotherapy facilities based on less sophisticated technology like the Cobalt 60 
based teletherapy and brachytherapy equipments that give acceptable good treatment 
outcome can help in the treatment of those already diagnosed with the disease. At The 
University College Hospital, Ibadan Nigeria, cobalt 60 brachytherapy source is used for high 
dose brachytherapy services with satisfactory outcome. This has served the purpose and is 
quite economical as the source is changed every 5 years instead of every 4 months as the 
case with the more popular iridium 190 source.  
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The HIV epidemic in the sub region has further increased the problem of cervical cancer as 
those so infected have rapid progression of the disease and usually have poorer outcome. 
Efforts to improve the control of the infection will also lead to the reduction in the mortality 
of cervical cancer. 
4.2.1 Pre-requisites for cervical screening: Infrastructure, funding, training 
The following were the submissions of Oxford University’s Africa – Oxford Cancer 
Consortium (AFROX) meeting towards prevention of cervical cancer in Africa at St 
Catherin’s College Oxford in March 2009. The meeting was chaired by Professor David Kerr 
of Oxford University and Professor Fiander Alison of The University of Cardiff. The 
following were the suggested prerequisite towards setting up effective screening programs 
in the sub region. 
To set up a cervical screening programme, it is vital to address the associated infrastructure, 
funding and training needs. The delegates at this workshop recommended that it would be 
important for: 
 Screening to be free at point of service and ideally as close to the people as possible. 
 The health systems for African countries differ, and so a unique approach would be 
required for each country. However, each African Government should be lobbied to set 
aside a certain amount of money per year to carry out cervical screening. It would be 
important to have this recognised by a separate sub‐section of the national budget. 
Finding sustainable funding for screening programmes is important – one way to 
achieve this could be for donors to insist that they would only fund a cervical cancer 
screening programme if the government agreed to provide funding support for the 
programme to continue after set‐up funding ended. 
 Building up political will and support for national funding support towards cervical 
cancer screening would be required. The First Ladies of Africa could have an important 
role in leading this. In Nigeria, the Governors’ wives have been keen supporters of 
cervical cancer screening. Community advocates and the media would also need to be 
mobilised. These groups would also have a key role in raising public awareness about 
the causes of cervical cancer and why treatment would be important. 
 Records and documentation of those being screened should be kept so we can tell how 
often or if they go for screening. This would also help to monitor whether it was simply 
the same people getting screened, or if the programme was succeeding in reaching new 
women. 
 If possible, screening should be integrated into existing programmes, such as 
programmes for breast cancer screening, sexual health programmes, etc 
 Training of health professionals to take smear tests and/or HPV tests would be 
necessary. Training of pathologists to read smear tests would also be critical. 
4.2.2 Evaluation & cost effectiveness of cervical screening 
The participants of this workshop discussed how to evaluate and measure the cost 
effectiveness and success of cervical screening programmes. They identified the following 
areas as being critical for consideration: 
www.intechopen.com
 
Topics on Cervical Cancer with an Advocacy for Prevention 70
1. Training 
- Are programs easy to staff? 
- Should pap smears be abandoned for developing countries due to lack of people to 
read them? 
- Work must be done by another health care level other than doctor – but problems 
arise when empowerment of lower personnel is met by resistance from doctors 
- Brain drain an issue – we must address the retention of health care personnel 
2. Cost 
- Need more interaction with health economists 
- Sustainability? 
- We must look into different financial flows, the idea of marketing campaigns and 
alternate financing schemes to raise substantial sums 
3. Coverage 
- Feasibility of “mother‐daughter” screening and vaccination project? 
- Feasibility of self‐screening? 
4. Political will 
- Need to sell a product to the policy makers? It is problematic to make a set of 
recommendations for African countries. The right screening depends on where you 
are. This is a highly heterogeneous environment and we can’t settle on a one‐size‐
fits‐all approach 
- Dogmatic decisions to be replaced by research‐based decisions…lobbying is good if 
it is on the basis of data. 
- Screening must be made part of a country’s health policy 
- Demonstration projects are a good way to show political leaders the efficacy of 
screening programs 
- Millennium Development Goals (MDG) goals 4 and 5 (reduction in child mortality 
and improvement in maternal health) are a useful platform to use – argue that HPV 
is part of maternal health. 
4.2.3 Creating a climate for informed decision-making in screening and vaccination 
The delegates at this workshop suggested the following steps should be taken, to create a 
climate of informed decision‐making about screening and vaccination programmes: 
 Informed consent has to be tailored appropriately to population. Informed consent 
means different things in different situations and with different people, so it has to be 
appropriate to population. 
 Screening should become part of routine care. 
 Policy makers are not yet aware of the cost/toll of cervical cancer in their countries. 
Consequently, the development of cancer registries is important. 
 Scientific evidence is important but a consensus statement can also be useful, for 
example from the world health organisation. 
 Need to show politicians that the impact of screening would be seen now. 
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 Survivors’ stories and the family stories of the women who have died of cervical cancer 
need to be told. Doctors and nurses should also tell stories about cervical cancer. We 
should not be afraid to tell individual stories; these are the ones that touch people. 
5. Conclusion 
Cervical cancer is still a problem in sub Sahara Africa. Concerted and focussed effort 
towards the reduction in the burden of the disease is urgently needed. The intensification of 
preventive, screening and therapeutic measures including education of the populace on 
these aspects can bring the disease under control as it is in the developed countries. Each 
country of Sub Sahara Africa should develop and implement sustainable preventive and 
screening programs using any of the available methods suitable and appropriate for their 
own setting instead of the present opportunistic screening activities prevalent in the region. 
Functional cancer registries are needed to analyze the pattern of the disease so as to help in 
planning control programs. There is also the need to address some of the conditions that 
predispose to practices that favor the development and spread of the disease. These 
conditions include poverty, illiteracy, political instability and widespread 
underdevelopment. 
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